Spots Global Cancer Trial Database for A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
Official Title: A Randomized Stratified Multicentre Phase II Clinical Trial of Single Agent ADI-PEG 20TM (Pegylated Arginine Deiminase) in Patients With Malignant Pleural Mesothelioma
Study ID: NCT01279967
Conditions
Interventions
Study Description
Brief Summary: To examine whether the arginine depleting drug, ADI-PEG 20, might be effective as a targeted therapy in patients with ASS-negative malignant pleural mesothelioma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Royal Sussex County Hospital, Brighton, , United Kingdom
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, , United Kingdom
Hull and East Yorkshire Hospitals NHS Trust,The Princess Royal Hospital, Hull, , United Kingdom
Barts and The London NHS, St Bartholomew's Hospital, London, , United Kingdom
Guy's and St Thomas' Foundation Trust, Guy's Hospital, London, , United Kingdom
University Hospital of South Manchester NHS Foundation Trust, Wythenshawe Hospital, Manchester, , United Kingdom
Southampton University Hospitals NHS Trust, Southampton General Hospital, Southampton, , United Kingdom
Contact Details
Name: Peter Szlosarek
Affiliation: Barts and the London NHS
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
